Actinogen Medical Limited (ASX:ACW)

Australia · Delayed Price · Currency is AUD

0.0470

+0.0020 (4.44%)

Apr 29, 2026, 3:44 PM AEST

67.86% (1Y)

Market Cap	161.62M
Revenue (ttm)	7.36M
Net Income (ttm)	-17.91M
Shares Out	3.59B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,445,226
Average Volume	3,093,324
Open	0.0450
Previous Close	0.0450
Day's Range	0.0450 - 0.0480
52-Week Range	0.0190 - 0.0720
Beta	1.00
RSI	61.60
Earnings Date	May 26, 2026

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 6

Stock Exchange Australian Securities Exchange

Ticker Symbol ACW

Full Company Profile

Financial Performance

In fiscal year 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.

Financial Statements

News

Actinogen Medical Transcript: Investor update

A positive interim analysis cleared safety and efficacy hurdles for the pivotal Alzheimer's trial, with robust funding secured to support operations beyond top-line results in November. Xanamem’s unique mechanism and strong clinical data position it favorably in a market seeking safer, more effective therapies.

3 months ago - Transcripts

Actinogen Medical Transcript: Status Update

Final enrollment in the pivotal Alzheimer's trial is complete, with interim analysis set for January and final results due in November next year. Xanamem's unique mechanism and strong safety profile position it as a leading oral therapy, with robust commercial and regulatory momentum.

4 months ago - Transcripts

Actinogen Medical Transcript: Status Update

Pivotal Alzheimer's trial for Xanamem® is fully enrolled, with interim analysis in January and final results expected mid-Q4 next year. Strong FDA support, robust financial runway, and high physician interest position the program for major milestones and potential partnerships.

6 months ago - Transcripts